Adding anifrolumab to standard treatment for systemic lupus erythematosus led to faster achievement of low disease activity ...

Saphnelo (Anifrolumab) is instrumental in addressing autoimmune conditions by targeting and inhibiting the type I interferon receptor. Since this receptor is frequently overactive in autoimmune ...

Saphnelo (anifrolumab) is the first biologic drug for SLE to be approved in Europe that is not restricted to patients with a high degree of disease activity, according to AZ, which also notes it ...

with newer medicines like GSK's Benlysta (belimumab), AstraZeneca's Saphnelo (anifrolumab), and Otsuka's Lupkynis (voclosporin). For Biogen, dapirolizumab pegol is part of a push into the ...

This disease is primarily treated with off-label drugs or newer meds in the form of GSK's Benlysta and AstraZeneca's Saphnelo. The most common form of the disease is systemic lupus erythematosus ...

Rheumatoid arthritis (RA) and lupus both cause joint pain and stiffness. Despite some similarities, it’s easy for doctors to distinguish them. RA has more debilitating effects on the joints ...

So, that's exciting news. The anifrolumab trial is moving along nicely. And so we might know soon, whether or not we might have an anti-interferon agent available for the treatment of lupus nephritis.

Eneboparatide met primary endpoint of normalising serum calcium in adults with hypoparathyroidism at 24 weeks in CALYPSO Phase III trial Trial continues as planned to 52 weeks to further ...